ZIMV vs. TBPH, FULC, PEPG, EHAB, CRBP, VYGR, LXEO, BMEA, BTMD, and EDIT
Should you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include Theravance Biopharma (TBPH), Fulcrum Therapeutics (FULC), PepGen (PEPG), Enhabit (EHAB), Corbus Pharmaceuticals (CRBP), Voyager Therapeutics (VYGR), Lexeo Therapeutics (LXEO), Biomea Fusion (BMEA), biote (BTMD), and Editas Medicine (EDIT). These companies are all part of the "medical" sector.
Theravance Biopharma (NASDAQ:TBPH) and ZimVie (NASDAQ:ZIMV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk.
In the previous week, Theravance Biopharma had 3 more articles in the media than ZimVie. MarketBeat recorded 10 mentions for Theravance Biopharma and 7 mentions for ZimVie. Theravance Biopharma's average media sentiment score of 0.78 beat ZimVie's score of 0.08 indicating that ZimVie is being referred to more favorably in the news media.
Theravance Biopharma has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, ZimVie has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500.
Theravance Biopharma presently has a consensus price target of $20.50, suggesting a potential upside of 120.67%. ZimVie has a consensus price target of $17.33, suggesting a potential upside of 1.84%. Given ZimVie's stronger consensus rating and higher probable upside, equities research analysts clearly believe Theravance Biopharma is more favorable than ZimVie.
Theravance Biopharma received 334 more outperform votes than ZimVie when rated by MarketBeat users. Likewise, 63.45% of users gave Theravance Biopharma an outperform vote while only 7.14% of users gave ZimVie an outperform vote.
Theravance Biopharma has higher earnings, but lower revenue than ZimVie. Theravance Biopharma is trading at a lower price-to-earnings ratio than ZimVie, indicating that it is currently the more affordable of the two stocks.
99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 95.6% of ZimVie shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by insiders. Comparatively, 5.0% of ZimVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ZimVie has a net margin of -56.31% compared to ZimVie's net margin of -72.79%. Theravance Biopharma's return on equity of 2.01% beat ZimVie's return on equity.
Summary
Theravance Biopharma beats ZimVie on 11 of the 18 factors compared between the two stocks.
Get ZimVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
